DANA-FARBER CANCER INSTITUTE
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Abemaciclib + Pembrolizumab In Glioblastoma
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT04118036
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Stereotactic Magnetic Resonance Guided Radiation Therapy
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 397
- Registration Number
- NCT04115254
- Locations
- ๐บ๐ธ
Brigham & Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT04081259
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT04071756
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
OPTimizing Treatment Focused Genetic Testing IN Cancer
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 301
- Registration Number
- NCT04066361
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04045470
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT04043845
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT04040725
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 101
- Registration Number
- NCT04033497
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 214
- Registration Number
- NCT04030507
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath